Association of statin prescription with small abdominal aortic aneurysm progression

American Heart Journal

Volumn 159, Issue 2, 2010, Pages 307-313

  Ferguson, Craig D ^a   Clancy, Paula ^a   Bourke, Bernard ^b   Walker, Philip J ^c   Dear, Anthony ^d   Buckenham, Tim ^e   Norman, Paul ^f   Golledge, Jonathan ^a  

^a Queensland Research Centre for Peripheral Vascular Disease   (Australia)

^b GOSFORD HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d BOX HILL HOSPITAL   (Australia)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; AGED; AORTA ANEURYSM; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR DISEASE; DISEASE COURSE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMAGING SYSTEM; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; ULTRASOUND; ULTRASOUND TRANSDUCER;

AGED; AORTIC ANEURYSM, ABDOMINAL; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE;

EID: 75449095892     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.11.016     Document Type: Article

References (40)

1. Begg S., Vos T., Barker B., et al. The burden of disease and injury in Australia 2003 (2007), Australian Institute of Health and Welfare, Canberra
2. Minino A.M., Heron M.P., Murphy S.L., et al. Deaths: final data for 2004. Natl Vital Stat Rep 55 (2007) 1-119
3. Fleming C., Whitlock E.P., Beil T.L., et al. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the US Preventive Services Task Force. Ann Intern Med 142 (2005) 203-211
4. Lederle F.A., Johnson G.R., Wilson S.E., et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 160 (2000) 1425-1430
5. Lederle F.A., Wilson S.E., Johnson G.R., et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 346 (2002) 1437-1444
6. United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 346 (2002) 1445-1452
7. Greenhalgh R.M., Brown L.C., Kwong G.P., et al. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet 364 (2004) 843-848
8. Brewster D.C., Cronenwett J.L., Hallett Jr. J.W., et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg 37 (2003) 1106-1117
9. Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 35 (2002) 72-79
10. Mosorin M., Juvonen J., Biancari F., et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 34 (2001) 606-610
11. Vammen S., Lindholt J.S., Ostergaard L., et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 88 (2001) 1066-1072
12. Lindholt J.S., Henneberg E.W., Juul S., et al. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 18 (1999) 52-57
13. Sukhija R., Aronow W.S., Sandhu R., et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 97 (2006) 279-280
14. Schouten O., van Laanen J.H., Boersma E., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 32 (2006) 21-26
15. Mosorin M., Niemela E., Heikkinen J., et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg (2008)
16. Schlosser F.J., Tangelder M.J., Verhagen H.J., et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 47 (2008) 1127-1133
17. Karlsson L., Bergqvist D., Lindback J., et al. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg 37 (2009) 420-424
18. Golledge J., Karan M., Moran C.S., et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J 29 (2008) 665-672
19. Golledge J., Clancy P., Jamrozik K., et al. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation 116 (2007) 2275-2279
20. Norman P., Spencer C.A., Lawrence-Brown M.M., et al. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation 110 (2004) 862-866
21. Golledge J., Muller J., Shephard N., et al. Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 27 (2007) 655-660
22. Golledge J., Jones L., Oliver L., et al. Folic acid, vitamin B12, MTHFR genotypes, and plasma homocysteine. Clin Chem 52 (2006) 1205-1206
23. Smallwood L., Allcock R., van Bockxmeer F., et al. Polymorphisms of the matrix metalloproteinase 9 gene and abdominal aortic aneurysm. Br J Surg 95 (2008) 1239-1244
24. Forsdahl S.H., Singh K., Solberg S., et al. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001. Circulation 119 (2009) 2202-2208
25. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423
26. Brady A.R., Thompson S.G., Fowkes F.G., et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110 (2004) 16-21
27. Santilli S.M., Littooy F.N., Cambria R.A., et al. Expansion rates and outcomes for the 3.0-cm to the 3.9-cm infrarenal abdominal aortic aneurysm. J Vasc Surg 35 (2002) 666-671
28. Shiraya S., Miyake T., Aoki M., et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 202 (2009) 34-40
29. Kalyanasundaram A., Elmore J.R., Manazer J.R., et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 43 (2006) 117-124
30. Abisi S., Burnand K.G., Humphries J., et al. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br J Surg 95 (2008) 333-337
31. Evans J., Powell J.T., Schwalbe E., et al. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 34 (2007) 302-303
32. Wilson W.R., Evans J., Bell P.R., et al. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 30 (2005) 259-262
33. Gottsater A., Flondell-Site D., Kolbel T., et al. Associations between statin treatment and markers of inflammation, vasoconstriction, and coagulation in patients with abdominal aortic aneurysm. Vasc Endovascular Surg 42 (2008) 567-573
34. Wilson W.R., Choke E.C., Dawson J., et al. Plasma matrix metalloproteinase levels do not predict tissue levels in abdominal aortic aneurysms suitable for elective repair. Vascular 16 (2008) 248-252
35. Dawson J., Cockerill G., Choke E., et al. Aortic aneurysms as a source of circulating interleukin-6. Ann N Y Acad Sci 1085 (2006) 320-323
36. Musial J., Undas A., Gajewski P., et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77 (2001) 247-253
37. Riesen W.F., Engler H., Risch M., et al. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23 (2002) 794-799
38. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
39. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
40. Moran C.S., Clancy P., Biros E., et al. Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm. Clin Endocrinol (Oxf) (2009) [Epub 2009 Apr 25]